Carvedilol in the treatment of chronic heart failure

Expert Opinion on Pharmacotherapy
G Moe

Abstract

Along with the angiotensin-converting enzyme inhibitors (ACEIs), the beta-adrenergic receptor blockers have gradually emerged to be standard in the therapy of heart failure. Individual beta-blockers that have been shown to reduce all-cause mortality in patients with heart failure include bisoprolol, metoprolol and carvedilol. Carvedilol distinguishes from the other beta-blockers as being a non-selective beta(1)- and beta(2)-receptor blocker with (1)-receptor blockade effect and anti-oxidant properties. The drug does not have sympathomimetic activity and has vasodilatory effects attributable to its (1)-receptor blockade property. Experimental and clinical studies have confirmed carvedilol's vasodilator, anti-oxidant and anti-apoptotic properties, which may contribute to its effect in reversing cardiac remodelling in animal models and patients with heart failure. These pharmacological properties render carvedilol a potentially useful agent in the treatment of patients with heart failure. Early studies of carvedilol in heart failure have reported beneficial haemodynamic effects but variable effects on exercise tolerance and clinical well being. The large-scale US Carvedilol Heart Failure Program and the Australian/New Zealand Hear...Continue Reading

References

Oct 1, 1975·British Heart Journal·F WaagsteinI Wallentin
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Jan 1, 1987·European Journal of Clinical Pharmacology·E von MöllendorffG Neugebauer
Sep 27, 1984·The New England Journal of Medicine·J N CohnT Rector
May 1, 1995·Journal of the American College of Cardiology·S L OlsenM R Bristow
Aug 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·W J LouisE L Conway
Jan 1, 1994·Immunology Today·T M Buttke, P A Sandstrom
Oct 17, 1996·The New England Journal of Medicine·J NarulaB A Khaw
Oct 24, 1996·The New England Journal of Medicine·L A Moyé, D Abernethy
Feb 1, 1997·European Heart Journal·M R CowieD E Grobbee
Feb 1, 1997·European Heart Journal·F PoussetM Komajda
Apr 17, 1997·The New England Journal of Medicine·G OlivettiP Anversa
Aug 1, 1997·Journal of the American Geriatrics Society·M W Rich
Mar 10, 1999·Cardiovascular Research·P K SingalD Kumar
Nov 7, 1999·Journal of the American College of Cardiology·J E SandersonK S Woo
Jan 26, 2000·International Journal of Cardiology·R SharmaS D Anker

❮ Previous
Next ❯

Citations

Nov 26, 2002·Biochemical Pharmacology·Chun-Peng LiuChung-Ren Jan
Sep 24, 2004·Basic & Clinical Pharmacology & Toxicology·Chun Peng Liu, Chung-Ren Jan
Sep 6, 2006·Journal of Cardiac Failure·Eri WatanabeMasatoshi Kawana
Jan 1, 2008·APMIS. Supplementum·Lars MoeEystein Glattre
Oct 9, 2020·Circulation. Arrhythmia and Electrophysiology·Niraj VarmaRaffaele Corbisiero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.